DOCSLIB.ORG

Endocrinology Test List Endocrinology Test List

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

For Endocrinologists Endocrinology Test List Endocrinology Test List Extensive Capabilities Managing patients with endocrine disorders is complex. Having access to the right test for the right patient is key. With a legacy of expertise in endocrine laboratory diagnostics, Quest Diagnostics offers an extensive menu of laboratory tests across the spectrum of endocrine disorders. This test list highlights the extensive menu of laboratory diagnostic tests we offer, including highly specialized tests and those performed using highly specific and sensitive mass spectrometry detection. It is conveniently organized by glandular function or common endocrine disorder, making it easy for you to identify the tests you need to care for the patients you treat. Comprehensive Care Quest Diagnostics Nichols Institute has been pioneering state-of-the-art endocrine testing for over four decades. Our commitment to innovative diagnostics and our dedication to quality and service means we deliver solutions that enable you to make informed clinical decisions for comprehensive patient management. We strive to remain at the forefront of innovation in endocrine testing so you can deliver the highest level of patient care. Abbreviations and Footnotes NDM, neonatal diabetes mellitus; MODY, maturity-onset diabetes of the young; CH, congenital hyperinsulinism; MSUD, maple syrup urine disease; IHH, idiopathic hypogonadotropic hypogonadism; BBS, Bardet-Biedl syndrome; OI, osteogenesis imperfecta; PKD, polycystic kidney disease; OPPG, osteoporosis-pseudoglioma syndrome; CPHD, combined pituitary hormone deficiency; GHD, growth hormone deficiency. The tests highlighted in green are performed using highly specific and sensitive mass spectrometry detection. Panels that include a test(s) performed using mass spectrometry are highlighted in yellow. For tests highlighted in blue, refer to the Athena Diagnostics website (athenadiagnostics.com/content/test-catalog) for test information. These tests are performed by Athena Diagnostics. † Multiple test codes are available. Refer to the Quest Diagnostics Nichols Institute Directory of Services or the online Test Center (QuestDiagnostics.com) for test information. 1 This test was developed and its performance characteristics have been determined by Quest Diagnostics Nichols Institute. Performance characteristics refer to the analytical performance of the test. 2 This test was developed and its performance characteristics have been determined by Athena Diagnostics. Performance characteristics refer to the analytical performance of the test. 3 This test was developed and its performance characteristics have been determined by Quest Diagnostics Nichols Institute. It has not been cleared or approved by the U.S. Food and Drug Administration. The FDA has determined that such clearance or approval is not necessary. Performance characteristics refer to the analytical performance of the test. 4 This test was performed using a kit that has not been cleared or approved by the FDA. The analytical performance characteristics of this test have been determined by Quest Diagnostics Nichols Institute. This test should not be used for diagnosis without confirmation by other medically established means. Reflex tests are performed at an additional charge. The following tests that are included in panels may be ordered separately: albumin, alkaline phosphatase, ALT, AST, bilirubin (direct and total), creatinine (serum and urine), electrolyte panel, hemoglobin, hepatic function panel, iron, phosphate, potassium, and total protein. Quest Diagnostics – Endocrinology Test List Test Code Test Name Adrenal Medullary Function/Catecholamines Congenital Adrenal Hyperplasia (CAH) Hemoglobin A1c with Calculated Mean Plasma Glucose 8181 1 (MPG) 39627(X) Catecholamines, Fractionated, 24-Hour Urine 14755(X) CAH (21-Hydroxylase Deficiency) Common Mutations Detects 11 CYP21A2 gene mutations and the 30kb deletion. 314(X) Catecholamines, Fractionated, Plasma 16802 Hemoglobin A1c with eAG 1 16072(X) CAH (21-Hydroxylase Deficiency) Rare Mutations 16715 Hemoglobin A1c with Reflex to GlycoMark® 5244 Catecholamines, Fractionated, Random Urine Includes sequencing of the entire CYP21A2 gene. 802 HNF4A (MODY1) DNA Sequencing and Deletion Test2 16381 Catecholamines, Fractionated, Supine, Plasma CAH Panel 1 (21-OH vs 11-βOH) 16382 Catecholamines, Fractionated, Upright, Plasma 15269(X) Includes 17-hydroxyprogesterone/11-deoxycortisol ratio, 37054(Z) β-Hydroxybutyrate 11-deoxycortisol/cortisol ratio, androstenedione, and total testosterone. 39626(X) Catecholamines, Fractionated, and VMA, 24-Hour Urine 36177(X) IA-2 Antibody CAH Panel 3 (aldosterone synthase deficiency) 1 16379 Chromogranin A, Electrochemiluminescence1 15273(X) Includes 17-OH progesterone/11-deoxycortisol ratio, and 36590 IGF Binding Protein-1 (IGFBP-1) 18-hydroxycorticosterone/aldosterone ratio. 2 39527(X) Homovanillic Acid, 24-Hour Urine 853 INS (NDM) DNA Sequencing Test CAH Panel 4 (17-OH deficiency in females) 561 Insulin 6346 Homovanillic Acid, Random Urine 15274(X) Includes progesterone/17-hydroxyprogesterone ratio, corticosterone, cortisol, aldosterone, and estradiol. 19548 Metanephrines, Fractionated, Free, LC/MS/MS, Plasma 36178 Insulin Autoantibody 15276(X) CAH Panel 6 (StAR deficiency) 36700 Insulin, Free (Bioactive) 14962(X) Metanephrines, Fractionated, LC/MS/MS, 24-Hour Urine Includes cortisol, pregnenolone, DHEA, and aldosterone. 91083 Insulin, LC/MS/MS 14961(X) Metanephrines, Fractionated, LC/MS/MS, Random Urine CAH Panel 6C (Full Screen) 834 IPF1 (MODY4) DNA Sequencing Test2 Pheochromocytoma Evaluation2 16978 Includes androstenedione, cortisol, 11-deoxycortisol, DHEA, 889 17-hydroxypregnenolone, 17-hydroxyprogesterone, progesterone, and 2 Detects mutations in RET, SDHB, and VHL. total testosterone. 841 IPF1 (NDM) DNA Sequencing Test 39517(X) VMA (Vanillylmandelic Acid), 24-Hour Urine 36741 Islet Cell Antibody Screen with Reflex to Titer2 15277(X) CAH Panel 7 (steroid replacement therapy monitoring) 1710 VMA (Vanillylmandelic Acid), Random Urine Includes androstenedione, total testosterone, 17-hydroxyprogesterone. 843 KCNJ11 (NDM) DNA Sequencing Test2 Adrenocortical Function See below for congenital adrenal hyperplasia. CAH Panel 8 (17-OH deficiency in males) Metabolic Syndrome and Glucose Control Including Insulin 15279(X) Includes progesterone/17-hydroxyprogesterone ratio, corticosterone, 2 91398 Includes cholesterol, total and HDL; glucose; insulin, LC/MS/MS; 815 ABCD1 (Adrenoleukodystrophy) DNA Sequencing Test cortisol, aldosterone, and total testosterone. triglycerides; and calculated components. 211 ACTH, Plasma CAH Panel 9 (3β-HSD deficiency) 15281 Microalbumin, 24-Hour Urine (with Creatinine) 15280(X) Includes 17-hydroxypregnenolone/17-hydroxyprogesterone ratio, 4645 Adrenal Antibody Screen with Reflex to Titer DHEA/androstenedione ratio, and cortisol. 4555 Microalbumin, 24-Hour Urine (without Creatinine) 19552(X) Aldosterone, 24-Hour Urine CAH Panel 11, Neonatal Random Urine 6517 Microalbumin, Random Urine (with Creatinine) 229 Includes 17-OH pregnanolone; 15, 17-(OH)2-pregnanolone; 16-OH 17674 Microalbumin, Random Urine (without Creatinine) 17181 Aldosterone, LC/MS/MS 10046(X) DHEA; pregnanetriol; tetrahydro 11-deoxycortisol; pregnanetriolone; 16- OH pregnenolone; pregnenetriol; tetrahydrocortisone; 6-OH tetrahydro Monogenic Diabetes (MODY) Evaluation2 † Aldosterone/Cortisol Ratio 11-deoxycortisol; tetrahydro 11-dehydrocorticosterone; A-cortolone; 885 Includes sequencing and deletion detection in GCK, HNF4A, TCF1, B-cortolone; and 6-OH tetrahydro 11-dehydrocorticosterone. and TCF2 and sequencing of IPF1. † Aldosterone/Cortisol Ratio, Adrenal Vein Sampling Congenital Adrenal Hyperplasia (CAH) Evaluation2 2 882 Neonatal Diabetes Mellitus Evaluation 16845 Aldosterone/Plasma Renin Activity Ratio, LC/MS/MS 879 Includes sequencing and deletion detection in CYP21A2 and Detects mutations in ABCC8, GCK, INS, IPF1, and KCNJ11. sequencing of CYP11B1. 5276(X) 3α-Androstanediol Glucuronide (3-Alpha Diol G) 678 Osmolality, Random Urine 875 CYP11B1 (CAH) DNA Sequencing Test2 17182 Androstenedione, LC/MS/MS 677 Osmolality, Serum 877 CYP17A1 DNA Sequencing Test2 6547(X) Corticosterone, LC/MS/MS 760(X) Proinsulin4 CYP21A2 (CAH) DNA Evaluation2 37371 Cortisol Binding Globulin (Transcortin) 880 Includes sequencing of the entire CYP21A2 gene, as well as detection of 34480 Somatostatin1 the common 30kb deletion. 37355(X) Cortisol, Free and Cortisone, 24-Hour Urine 804 TCF1 (MODY3) DNA Sequencing and Deletion Test2 30543 11-Deoxycortisol, LC/MS/MS, Serum 37077(X) Cortisol, Free and Total, LC/MS/MS 805 TCF2 (MODY5) DNA Sequencing and Deletion Test2 878 HSD3B2 DNA Sequencing Test2 36423(X) Cortisol, Free, LC/MS/MS Dynamic Testing 17180 17-Hydroxyprogesterone, LC/MS/MS 11280(X) Cortisol, Free, LC/MS/MS, 24-Hour Urine 17832(X) Aldosterone, Response to ACTH Stimulation, LC/MS/MS 17654(X) 17-Hydroxyprogesterone, Neonatal/Infant 90582 Cortisol, Free, LC/MS/MS, Second Void Urine Androstenedione Response to ACTH Stimulation, 2 19511(X) 19897(X) Cortisol, LC/MS/MS, Saliva Lipoid CAH (StAR) Evaluation LC/MS/MS 874 Detects mutations (including point mutations, deletions, insertions, and 11281(X) Cortisol, Total, LC/MS/MS rearrangements) in StAR. 10068(X) Catecholamines, Total, Suppression by Clonidine, Plasma 37554(X) Cortisone, 24-Hour Urine 738 Pregnanetriol, Urine 16434 Cortisol, Free, Response to ACTH Stimulation 37098(X) Cortisone, Serum3 Steroid Panel, 21-Hydroxylase Deficiency/ 38149(X) Cortisol Response
Recommended publications
  • Ptvg-HP Vaccine Protocol

    Ptvg-HP Vaccine Protocol

    Version 10/7/2015 Randomized Phase II Trial of a DNA Vaccine Encoding Prostatic Acid Phosphatase (pTVG-HP) versus GM-CSF Adjuvant in Patients with Non-Metastatic Prostate Cancer CO 08801 Investigational Agent: BB IND 12109 - pTVG-HP DNA encoding human prostatic acid phosphatase Study Sponsors: 56 patients – treated at UWCCC and UCSF Department of Defense Prostate Cancer Research Program federal grant 50 patients in biomarker cohort – treated at UWCCC, UCSF and JHU Madison Vaccines Inc. (MVI) corporate sponsor STUDY SITE INFORMATION Study Sites: University of Wisconsin Carbone Cancer Center (UWCCC) 1111 Highland Avenue Madison, WI 53705 University of California San Francisco (UCSF) Johns Hopkins School of Medicine (JHU) Study Principal Investigator: Douglas G. McNeel, M.D., Ph.D. UWCCC 7007 Wisconsin Institutes for Medical Research 1111 Highland Ave. Madison, WI 53705 Tel: (608) 263-4198 Fax: (608) 265-0614 [email protected] UWCCC Local Principal Investigator : Glenn Liu, MD UWCCC 7051 Wisconsin Institutes for Medical Research 1111 Highland Ave. Madison, WI 53705 Tel : (608) 265-8689 Fax : (608) 265-5146 [email protected] Medical Monitor: Mark Albertini, M.D. UWCCC 600 Highland Ave. K6/5 CSC Madison, WI 53792 Tel: (608) 265-8131 Fax: (608) 265-8133 [email protected] Other UWCCC Investigators: Joshua Lang, M.D. – Clinical Investigator Christos Kyriakopolous, M.D. – Clinical Investigator Robert Jeraj, Ph.D. – Medical Physics, Quantitative Total Bone Imaging Scott Perlman, M.D. – Nuclear Medicine UCSF Principal Investigator: Lawrence Fong, M.D. JHU Principal Investigator: Emmanuel Antonarakis, MD Study Coordinator: Mary Jane Staab, R.N. B.S.N. UWCCC 600 Highland Ave.
  • Endocrinology Resident Profile Jill Trinacty

    Endocrinology Resident Profile Jill Trinacty

    Endocrinology Resident Profile Jill Trinacty July 2017 About me My name is Jill Trinacty, and I was raised in Berwick, Nova Scotia. I went completed my BSc. (Honours) at Saint Francis Xavier University in Antigonish, Nova Scotia. I spent a year as the Active Living Coordinator with the Town of Kentville then completed my MD at Dalhousie University. I moved to Ottawa, Ontario in 2013 for my residency in Internal Medicine at the University of Ottawa and am currently a PGY-5 in Endocrinology and Metabolism. Why I chose General Endocrinology In medical school I became interested in almost every area of medicine, but ultimately applied to internal medicine for a number of reasons. I have always been interested in Endocrinology, specifically diabetes. Diabetes affects so many people in our communities and can have significant morbidity and mortality. I liked the detail of internal medicine and the complexity of patients. Having some previous experience in public health, I knew that I wanted a career that would allow me to discuss lifestyle changes as an aspect of therapy – specifically nutrition and physical activity. I also wanted a career that would allow for work/life balance. Seeing the day-to-day lifestyle of each internal medicine subspecialty confirmed that Endocrinology was the right fit for me. Clinical Life What does a typical day of clinical duties involve? This is an example of my typical daily and weekly schedule: Endocrinology – A typical day 7:30 – 8:00 Clerical work / Chief resident duties. Review emails, follow up on patient results, approve vacation requests, make call schedule.
  • Thursday 23 June 2016 – Morning A2 GCE HUMAN BIOLOGY F225/01 Genetics, Control and Ageing *5884237032* Candidates Answer on the Question Paper

    Thursday 23 June 2016 – Morning A2 GCE HUMAN BIOLOGY F225/01 Genetics, Control and Ageing *5884237032* Candidates Answer on the Question Paper

    Oxford Cambridge and RSA Thursday 23 June 2016 – Morning A2 GCE HUMAN BIOLOGY F225/01 Genetics, Control and Ageing *5884237032* Candidates answer on the Question Paper. OCR supplied materials: Duration: 2 hours None Other materials required: • Electronic calculator • Ruler (cm/mm) *F22501* INSTRUCTIONS TO CANDIDATES • Write your name, centre number and candidate number in the boxes above. Please write clearly and in capital letters. • Use black ink. HB pencil may be used for graphs and diagrams only. • Answer all the questions. • Read each question carefully. Make sure you know what you have to do before starting your answer. • Write your answer to each question in the space provided. If additional space is required, you should use the lined page(s) at the end of this booklet. The question number(s) must be clearly shown. • Do not write in the bar codes. INFORMATION FOR CANDIDATES • The number of marks is given in brackets [ ] at the end of each question or part question. • The total number of marks for this paper is 100. • Where you see this icon you will be awarded marks for the quality of written communication in your answer. • You may use an electronic calculator. • You are advised to show all the steps in any calculations. • This document consists of 24 pages. Any blank pages are indicated. © OCR 2016 [K/500/8502] OCR is an exempt Charity DC (NH/SW) 119808/4 Turn over 2 Answer all the questions. 1 Excretion is the removal of metabolic waste products from the body. The kidney is one of the organs involved in excretion.
  • Prenatal Growth Restriction, Retinal Dystrophy, Diabetes Insipidus and White Matter Disease: Expanding the Spectrum of PRPS1-Related Disorders

    Prenatal Growth Restriction, Retinal Dystrophy, Diabetes Insipidus and White Matter Disease: Expanding the Spectrum of PRPS1-Related Disorders

    European Journal of Human Genetics (2015) 23, 310–316 & 2015 Macmillan Publishers Limited All rights reserved 1018-4813/15 www.nature.com/ejhg ARTICLE Prenatal growth restriction, retinal dystrophy, diabetes insipidus and white matter disease: expanding the spectrum of PRPS1-related disorders Almundher Al-Maawali1,2, Lucie Dupuis1, Susan Blaser3, Elise Heon4, Mark Tarnopolsky5, Fathiya Al-Murshedi2, Christian R Marshall6,7, Tara Paton6,7, Stephen W Scherer6,7 for the FORGE Canada Consortium9, Jeroen Roelofsen8, Andre´ BP van Kuilenburg8 and Roberto Mendoza-Londono*,1 PRPS1 codes for the enzyme phosphoribosyl pyrophosphate synthetase-1 (PRS-1). The spectrum of PRPS1-related disorders associated with reduced activity includes Arts syndrome, Charcot–Marie–Tooth disease-5 (CMTX5) and X-linked non-syndromic sensorineural deafness (DFN2). We describe a novel phenotype associated with decreased PRS-1 function in two affected male siblings. Using whole exome and Sanger sequencing techniques, we identified a novel missense mutation in PRPS1. The clinical phenotype in our patients is characterized by high prenatal maternal a-fetoprotein, intrauterine growth restriction, dysmorphic facial features, severe intellectual disability and spastic quadraparesis. Additional phenotypic features include macular coloboma-like lesions with retinal dystrophy, severe short stature and diabetes insipidus. Exome sequencing of the two affected male siblings identified a shared putative pathogenic mutation c.586C4T p.(Arg196Trp) in the PRPS1 gene that was maternally inherited. Follow-up testing showed normal levels of hypoxanthine in urine samples and uric acid levels in blood serum. The PRS activity was significantly reduced in erythrocytes of the two patients. Nucleotide analysis in erythrocytes revealed abnormally low guanosine triphosphate and guanosine diphosphate.
  • Evaluation of Deficiency of 21 -Hydroxylation in Patients with Congenital Adrenal Hyperplasia 0

    Evaluation of Deficiency of 21 -Hydroxylation in Patients with Congenital Adrenal Hyperplasia 0

    Arch Dis Child: first published as 10.1136/adc.43.230.410 on 1 August 1968. Downloaded from Arch. Dis. Childh., 1968, 43, 410. Evaluation of Deficiency of 21 -hydroxylation in Patients with Congenital Adrenal Hyperplasia 0. M. GALAL, B. T. RUDD, and N. M. DRAYER From the Institute of Child Health, University of Birmingham Congenital adrenal hyperplasia can manifest therapy in these 13 children started within the first 3 itself in a variety of clinical and biochemical weeks of life. abnormalities (Bongiovanni and Root, 1963). The In addition to the 18 patients with congenital adrenal salt-losing tendency in some of these patients can hyperplasia, 3 children with shortness of stature and 3 with early signs of puberty were given ACTH to be due to the absence of specific enzymes: dehydro- investigate their adrenal function. None of these genases or hydroxylases (Bongiovanni and Root, patients had received steroids and all had normal free 1963; Ulick et al., 1964; Visser and Cost, 1964). cortisol and 17-hydroxycorticosteroid urinary excretion In addition to the impaired production of certain rates. The age and sex of the patients in the 3 groups steroids, antagonism by steroids or other compounds and details of the steroid therapy are listed in Table I. could, theoretically, account for the salt-losing tendency (Neher, Meystre, and Wettstein, 1959; ACTH test. Twenty-four hour urine collections Jacobs et al., 1961). were obtained before and during ACTH stimulation. The purpose ofthis study was to discover whether, ACTH gel (Organon) was given intramuscularly at a copyright. despite the continuation of steroid therapy, stimula- dose of 20 I.U.
  • Chronic Fatigue: Is It Endocrinology?

    Chronic Fatigue: Is It Endocrinology?

    I ORIGINAL PAPERS Chronic fatigue: is it endocrinology? Kate M Evans, Daniel E Flanagan and Terence J Wilkin Kate M Evans ABSTRACT – Fatigue and stress-related illnesses imal physical signs where initial investigations are MRCP, Consultant often become diagnoses of exclusion after exten- normal. It is possible to reassure the individual that Physician sive investigation. ‘Tired all the time’ is a frequent there is no significant disease at that point but there Daniel E reason for referral to the endocrine clinic, the are no clear data to address the question of whether Flanagan implicit question being – is there a subtle overt pathology will develop in the future. This paper FRCP, Consultant endocrine pathology contributing to the patient’s reports audit findings for a cohort of patients seen Physician symptoms? Often initial assessment suggests not in an endocrinology clinic with fatigue, including but there are no clear data to address the ques- Terence J Wilkin outcome data at five or more years later. FRCP, Professor of tion of whether overt pathology will develop in the Medicine future. This study observed outcomes after five Subjects and methods years in 101 consecutive and unselected referrals Department of to secondary care for ‘fatigue?cause’, where initial Consecutive and unselected referrals from primary Endocrinology and assessment did not suggest treatable endocrine care to the endocrinology service over a four-year Metabolism, Peninsula Medical pathology. The findings suggest that the clinical period (1995–99) were identified from the clinic School, Plymouth diagnosis of fatigue, based on history and tests to database. Referrals were included in the dataset if the and Derriford exclude anaemia, hypothyroidism and diabetes, is primary reason for referral or primary symptom was Hospital, Plymouth secure: these patients do not subsequently fatigue.
  • 400 We Have Studied Six Infants and Young Children with Hyper

    400 We Have Studied Six Infants and Young Children with Hyper

    400 ABSTRACTS We have studied six infants and young children with hyper- ml plasma sample has been evaluated for the rapid (4—6 hr) diag- thyroidism whose clinical course differs from the few reports of nosis of CAH. Pet ether, benzene and methylene chloride extracts others. Neonatal and early childhood hyperthyroidism are usually of plasma are quantitated by competitive protein binding using thought of as separate, rare, and transient disorders seldom re- 17-hydroxyprogesterone (17-OHP), 11-deoxycortisol (cmpd S), quiring long term treatment. 1) Our cases have not been tran- and cortisol standards, respectively, for comparison. The observed sient: 2) they have occurred in families with a high incidence of plasma steroid concentrations are expressed as a ratio of adult Graves disease. "17-OHP" + "cmpd S" to "cortisol" since comparison of ratios, Four were born with Graves disease. Three continue to be rather than absolute values, has been found to differentiate nor- hyperthyroid at ages 1, 5, and 6 years. Two developed Graves mals from patients more clearly. disease at ages 3 and 8 years and continue on anti-thyroid medi- Plasma samples have been obtained from six normal children cation. Graves disease occurred in five of the six mothers and aged 4 days-7 yrs following administration of ACTH, from six was apparent during gestation in four. The sixth mother, mother adults with 11-hydroxylation impaired by the administration of of a neonatal case, has never had overt Graves disease, but female metyrapone, and from three children aged 11 mos, 6 yrs and 8 members of four generations have had Graves disease.
  • Tumor Markers

    Tumor Markers

    Tumor Markers Alan H.B. Wu, Ph.D. Professor, Laboratory Medicine, UCSF Section Chief, Clinical Chemistry, Toxicology, Pharmacogenomics Laboratory, SFGH Learning objectives • Know the ideal characteristics of a tumor marker • Understand the role of tumor markers for diagnosis and management of patients with cancer. • Know the emerging technologies for tumor markers • Understand the role of tumor markers for therapeutic selection How do we diagnose cancer today? Physical Examination Blood tests CT scans Biopsy Human Prostate Cancer Normal Blood Smear Chronic Myeloid Leukemia Death rates for cancer vs. heart disease New cancer cases per year Cancer Site or Type New Cases Prostate 218,000 Lung 222,500 Breast 207,500 Colorectal 149,000 Urinary system 131,500 Skin 68,770 Pancreas 43,100 Ovarian 22,000 Myeloma 20,200 Thyroid 44,700 Germ Cell 9,000 Types of Tumor Markers • Hormones (hCG; calcitonin; gastrin; prolactin;) • Enzymes (acid phosphatase; alkaline phosphatase; PSA) • Cancer antigen proteins & glycoproteins (CA125; CA 15.3; CA19.9) • Metabolites (norepinephrine, epinephrine) • Normal proteins (thyroglobulin) • Oncofetal antigens (CEA, AFP) • Receptors (ER, PR, EGFR) • Genetic changes (mutations/translocations, etc.) Characteristics of an ideal tumor marker • Specificity for a single type of cancer • High sensitivity and specificity for cancerous growth • Correlation of marker level with tumor size • Homogeneous (i.e., minimal post-translational modifications) • Short half-life in circulation Roles for tumor markers • Determine risk (PSA)
  • LEUKOCYTE SURFACE ORIGIN of HUMAN At-ACID GLYCOPROTEIN (OROSOMUCOID)*

    LEUKOCYTE SURFACE ORIGIN of HUMAN At-ACID GLYCOPROTEIN (OROSOMUCOID)*

    LEUKOCYTE SURFACE ORIGIN OF HUMAN at-ACID GLYCOPROTEIN (OROSOMUCOID)* BY CARL G. GAHMBERG AND LEIF C. ANDERSSON (From the Department of Bacteriology and Immunology, and the Transplantation Laboratory, Department of Surgery IV, University of Helsinki, Helsinki 29, Finland) Human al-acid glycoprotein (orosomucoid) (o~I-AG)1 constitutes the main component of the seromucoid fraction of human plasma. It belongs to the acute phase proteins, which increase under conditions such as inflammation, pregnancy, and cancer (1, 2). al-AG has previously been found to be synthesized in liver (3), and after removal of terminal sialic acids, it is cleared from the circulation by binding to a receptor protein on liver cell plasma membranes (4). The structure of al-AG is well known. It is composed of a single polypeptide chain and contains 245% carbohydrate including a large amount of sialic acid. The carbohydrate is located in the first half of the peptide chain linked to asparagine residues (5, 6). The function of al-AG is unclear. However, Schmid et al. (5) and Ikenaka et al. (7) and reported that the amino acid sequence of the protein shows a significant homology with human IgG. This finding and the striking increase in inflammatory and lymphopro- liferative disorders made us consider the possibility that leukocytes could be directly involved in the synthesis and release of a~-AG. We report here the presence of a membrane form of al-AG, with an apparent tool wt of 52,000, on normal human lymphocytes, granulocytes, and monocytes. By the use of internal labeling with [3H]leucine in vitro, we demonstrate that the membrane protein is synthesized by lymphocytes.
  • Diabetes Insipidus

    Diabetes Insipidus

    Your feelings about Infertility conditions series: › Diabetes insipidus The Pituitary Foundation Information Booklets Working to support pituitary patients, their carers & families The Pituitary Foundation is a charity working About this booklet in the United Kingdom and Republic of The aim of this booklet is to provide information Ireland supporting patients with pituitary about diabetes insipidus. conditions, their carers, family and friends. You may find that not all of the information Our aims are to offer support through the applies to you in particular, but we hope it helps pituitary journey, provide information to the you to understand your condition better and community, and act as the patient voice to raise offers you a basis for discussion with your GP awareness and improve services. and endocrinologist. What is diabetes insipidus and why do we get it? 3 The two forms of diabetes insipidus 5 How is DI diagnosed and treated? 7 How is DI diagnosed? 7 What tests are carried out and how will they feel? 7 How is DI treated? 7 Aftercare 9 How will diabetes insipidus affect my life? 10 Prescriptions 10 Driving 10 Employment problems 10 Insurance & pensions 10 Personal medical identification 11 Toilet facilities card 11 National key scheme 11 Common questions 12-13 What DI means to me - a patient's story 14 Membership & donation information 15 2 Diabetes insipidus What is diabetes insipidus (DI) and why do we get it? Diabetes insipidus (DI) is caused by a problem with either the production, or action, of the hormone vasopressin (AVP). If you have DI your kidneys are unable to retain water.
  • Comprehensive Urinary Hormone Assessments

    Comprehensive Urinary Hormone Assessments

    ENDOCRINOLOGY Complete Hormones – Analytes Comprehensive Urinary Hormone Assessments Urinary Pregesterones Urinary Glucocorticoids Urinary Androgens Urinary Estrogens Pregnanediol Cortisol, Free Testosterone Estrone Pregnanetriol Total 17-Hydroxy-corticosteroids Dehydroepiandrosterone (DHEA) Estradiol allo-Tetrahydrocortisol, a-THF Total 17-Ketosteroids Estriol Tetrahydrodeoxycortisol Androsterone 2-Hydroxyestrone Tetrahydrocortisol, THF Etiocholanolone 2-Methoxyestrone Tetrahydrocortisone, THE 11-Keto-androsterone 4-Hydroxyestrone 17-Hydroxysteriods, Total 11-Keto-etiocholanolone 4-Methoxyestrone Pregnanetriol 11-Hydroxy-androsterone 16α-Hydroxyestrone 11-Hydroxy-etiocholanolone 2-Hydroxy-estrone:16α-Hydroxyestrone ratio 2-Methoxyestrone:2-Hydroxyestrone ratio CLINICIAN INFORMATION 4-Methoxyestrone:4-Hydroxyestrone ratio ADVANCING THE CLINICAL UTILITY OF URINARY HORMONE ASSESSMENT Specimen Requirements Complete Hormones™ is Genova’s most comprehensive • 120 ml aliquot, refrigerated until shipped, urinary hormone profile, and is designed to assist with the from either First Morning Urine or 24-Hour clinical management of hormone-related symptoms. This profile Collection Why Use Complete Hormones? assesses parent hormones and their metabolites as well as key metabolic pathways, and provides insight into the contribution Hormone testing is an effective tool for assessing Related Profiles: that sex hormones may have in patients presenting with and managing patients with hormone- related symptoms. This profile supports: • Male Hormonal Health™
  • Differential Gene Expression in Oligodendrocyte Progenitor Cells, Oligodendrocytes and Type II Astrocytes

    Differential Gene Expression in Oligodendrocyte Progenitor Cells, Oligodendrocytes and Type II Astrocytes

    Tohoku J. Exp. Med., 2011,Differential 223, 161-176 Gene Expression in OPCs, Oligodendrocytes and Type II Astrocytes 161 Differential Gene Expression in Oligodendrocyte Progenitor Cells, Oligodendrocytes and Type II Astrocytes Jian-Guo Hu,1,2,* Yan-Xia Wang,3,* Jian-Sheng Zhou,2 Chang-Jie Chen,4 Feng-Chao Wang,1 Xing-Wu Li1 and He-Zuo Lü1,2 1Department of Clinical Laboratory Science, The First Affiliated Hospital of Bengbu Medical College, Bengbu, P.R. China 2Anhui Key Laboratory of Tissue Transplantation, Bengbu Medical College, Bengbu, P.R. China 3Department of Neurobiology, Shanghai Jiaotong University School of Medicine, Shanghai, P.R. China 4Department of Laboratory Medicine, Bengbu Medical College, Bengbu, P.R. China Oligodendrocyte precursor cells (OPCs) are bipotential progenitor cells that can differentiate into myelin-forming oligodendrocytes or functionally undetermined type II astrocytes. Transplantation of OPCs is an attractive therapy for demyelinating diseases. However, due to their bipotential differentiation potential, the majority of OPCs differentiate into astrocytes at transplanted sites. It is therefore important to understand the molecular mechanisms that regulate the transition from OPCs to oligodendrocytes or astrocytes. In this study, we isolated OPCs from the spinal cords of rat embryos (16 days old) and induced them to differentiate into oligodendrocytes or type II astrocytes in the absence or presence of 10% fetal bovine serum, respectively. RNAs were extracted from each cell population and hybridized to GeneChip with 28,700 rat genes. Using the criterion of fold change > 4 in the expression level, we identified 83 genes that were up-regulated and 89 genes that were down-regulated in oligodendrocytes, and 92 genes that were up-regulated and 86 that were down-regulated in type II astrocytes compared with OPCs.